<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883790</url>
  </required_header>
  <id_info>
    <org_study_id>HF02-13-42</org_study_id>
    <nct_id>NCT02883790</nct_id>
  </id_info>
  <brief_title>Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled, Study to Evaluate the Effects of Melatonin (Somnage®- Food Supplement) in the Management on Sleep Quality and Mood Alteration in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this placebo-controlled randomized study is to evaluate the effects of Melatonin
      1mg/Zn 30% VNR/Mg 100% VNR (food supplement) in the management on sleep quality and mood
      alteration in cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the activity of a food supplement, made of
      Melatonin, Zinc and Magnesium on sleep quality in cancer patients, compared to placebo.

      Secondary objectives are to evaluate the activity of Melatonin, Zinc and Magnesium on the
      quality of life, on the fatigue and on the mood alteration in cancer patients.

      The study will also assess the safety of the food supplement under investigation.

      In two small subgroups, on voluntary basis, some additional assessments will be done (arm
      band, nutritional change diary, DXA in one group and activity tracker in another group)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of sleep assessed using the PSQI scale</measure>
    <time_frame>up to 63 days of treatment</time_frame>
    <description>PSQI scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective sleep quality through sleep diary</measure>
    <time_frame>up to 63 days of treatment</time_frame>
    <description>Sleep diary analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall fatigue assessed using the Brief Fatigue Inventory (BFI) questionnaire</measure>
    <time_frame>up to 63 days of treatment</time_frame>
    <description>Fatigue assessment through Brief Fatigue Inventory (BFI) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life evaluated according to SF-12 scale</measure>
    <time_frame>up to 63 days of treatment</time_frame>
    <description>Quality of Life evaluated according to SF-12 scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number and typology of adverse events</measure>
    <time_frame>up to 63 days of treatment</time_frame>
    <description>Number and typology of adverse events (AEs), Physical examination, Vital signs, Laboratory tests (hematology, blood chemistry)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Somnage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration o.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Somnage</intervention_name>
    <description>Melatonin 1mg, Zinc, Magnesium</description>
    <arm_group_label>Somnage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Females aged between 18 and 75 years (included)

          2. Pittsburgh Sleep Quality Index (PSQI) score ≥ 5

          3. Diagnosed for breast, lung or colon-rectal cancer

          4. Metastatic first chemotherapy line

          5. Planned duration of chemotherapy treatment at least 63 days

          6. Negative to pregnancy test

          7. Patients able to swallow

        Exclusion Criteria:

          1. Known hypersensitivity reaction to Melatonin, Zinc or Magnesium or any components of
             the product

          2. Known current drug or alcohol abuse.

          3. Use of other investigational drug(s) within 30 days before study entry or during the
             study

          4. Clinically significant findings on physical examination or presence of known
             clinically significant disease that would interfere with study evaluation

          5. Patients treated with benzodiazepines, hypnotic, anticonvulsant, antipsychotic or
             antidepressant drugs in the two months before screening visit

          6. Patients receiving or planned to receive warfarin

          7. Chronic treatment with steroids with daily dose over 10 mg prednisone or equivalent
             product

          8. Brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rondanelli Mariangela, Prof. MD.</last_name>
    <phone>+39 0382 381149</phone>
    <email>mariangela.rondanelli@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori di Milano</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plantanida Marco, MD</last_name>
      <phone>+39 02 2390</phone>
      <phone_ext>2880</phone_ext>
      <email>marco.plantanida@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.E.O. Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Locatelli Marzia Adelia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cortinovis Diego, MD</last_name>
      <phone>+39 039 2333203</phone>
      <email>d.cortinovis@hsgerardo.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Matteo di Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedrazzoli Paolo, MD</last_name>
      <phone>+39 0382 501659</phone>
      <email>p.pedrazzoli@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda di Servizi alla Persona di Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rondanelli Mariangela, Prof. MD.</last_name>
      <phone>+39 0382 381149</phone>
      <email>mariangela.rondanelli@unipv.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

